NAUSEA and Clindamycin

PatientsVille

Find and Compare Side Effects

NAUSEA Symptoms and Causes

Nausea is an uneasy or unsettled feeling in the stomach together with an urge to vomit. Nausea and vomiting, or throwing up, are not diseases. They can be symptoms of many different conditions. These include morning sickness during pregnancy, infections, migraine headaches, motion sickness, food poisoning, cancer chemotherapy or other medicines.

For vomiting in children and adults, avoid solid foods until vomiting has stopped for at least six hours. Then work back to a normal diet. Drink small amounts of clear liquids to avoid dehydration.

Nausea and vomiting are common. Usually, they are not serious. You should see a doctor immediately if you suspect poisoning or if you have

Vomited for longer than 24 hours

Blood in the vomit

Severe abdominal pain

Headache and stiff neck

Signs of dehydration, such as dry mouth, infrequent urination or dark urine

NAUSEA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

To evaluate the role of some predictive biomarkers for chemotherapy-induced nausea and vomiting; To evaluate the clinical characteristics related to chemotherapy-induced nausea and vomiting in Korean patients

Proportion of patients with no nausea, defined as a response of 0 in the nausea item of Nausea and Vomiting Daily Diary/Questionnaire; Nausea scores measured by the Nausea and Vomiting Daily Diary/Questionnaire; Complete response, defined as no emetic episodes and no use of rescue medication measured by the Nausea and Vomiting Daily Diary/Questionnaire; Incidence of potential toxicities related to olanzapine as measured by the Nausea and Vomiting Daily Diary/Questionnaire; Frequency of rescue medication repeatedly measured by the Nausea and Vomiting Daily Diary/Questionnaire

Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment); Proportion of patients with complete response, defined as no emesis and no use of rescue medication in delayed phase (within 2-4 days of treatment); Proportion of patients with complete response, defined as no nausea, defined as Visual Analog Scale (VAS) less than 5 mm on a 0-100mm horizontal scale in acute phase (within 24 hours of treatment); Proportion of patients with complete response, defined as no nausea, defined as VAS less than 5 mm on a 0-100mm horizontal scale in delayed phase (within 2-4 days of treatment); Proportion of patients with partial response, defined as 2 or fewer episodes of emesis (Common Terminology Criteria for Adverse Events [CTCAE] version 4.0 grade 1-2), regardless of the use of rescue antiemetic medications (in acute and delayed phase); Proportion of patients with treatment failures, defined as more than 2 episodes of emesis (CTCAE version 4.0 grade 2 or greater), regardless of the use of rescue antiemetic medications; Proportion of patients with partial response, defined as no significant nausea, defined as VAS less than 25 mm on a 0-100mm horizontal scale (in acute and delayed phase); Proportion of patients who developed nausea and vomiting in the first course of treatment out of all enrolled patients; Proportion of patients who developed grade 1, 2, 3, or 4 nausea and vomiting with all courses of treatment out of all patients who developed nausea and vomiting; Proportion of patients who developed nausea and vomiting on all courses; Proportion of patients who experience grade 1, 2, 3, or 4 adverse events out of all patients who have received study drugs; Proportion of patients who missed 0, 1, or more than 2 doses of scheduled antiemetic medication at home on days 2 to 3, out of all patients

Complete Response rate (no vomiting and no rescue anti-emetic therapy); Complete Response rate; Proportion of patients who did not vomit; No Significant Nausea: The proportion of patients who did not experience any nausea ≥ 3 on 0 - 10 scale; No Nausea: The proportion of patients who did not experience any nausea. Nausea = 0 on 0 - 10 scale; Complete Protection: The proportion of patients who did not vomit, require rescue therapy, or have nausea ≥ 3 on 0 - 10 scale; Total Protection: The proportion of patients who did not vomit, require rescue therapy, or have any nausea (Nausea = 0 on 0 - 10 scale).; Vomiting frequency: The frequency of vomiting (# episodes per week) in patients who did vomit at least once.; Nausea frequency: The frequency of nausea (Nausea > 0 in a given week/ number of weeks during overall period of radiation treatment); Significant Nausea frequency: The frequency of significant nausea (Nausea ≥ 3 in a given week/ number of weeks during overall period of radiation treatment); Frequency of rescue medication use: The number of days in which rescue medication was taken / number of days of radiotherapy; Time to Failure: The time period in days from the start of radiation until the first vomiting episode or use of rescue medication for all patients and for the subset of patients who do not have a Complete Response.; All adverse events that occur during radiation treatment with assessment of severity (CTC v.3) and relationship to study drug.

the incidence and severity of any nausea, emetic episodes (retching or vomiting), or both (i.e., postoperative nausea and vomiting) during the first 24 postoperative hours.; The incidence and severity of throat pain; the incidence of oral mucosal injury; satisfactory scores of patients

Number of PRN Doses of anti-emetics needed; Visual Analogue Scale of nausea; duration of perceived nausea; number of vomits per 24 hours; volume of vomit per 24 hours; adverse effects of acupressure; measure of whether the patient felt the intervention helped.

The Proportion of Participants with Overall No Vomiting for the Overall Stage; Number of Participants with a Complete Response - Overall, Acute, and Delayed; Time to First Vomiting Event Overall; Number of Participants with No Vomiting and No Significant Nausea; Number of Participants with No Impact on Daily Life - Overall; Number of Participants with No Use of a Rescue Therapy - Overall, Acute, and Delayed; Number of Participants with One or More Clinical Adverse Events; No Vomiting - Acute and Delayed

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.